6 Best Peptides for Dry Eyes

What to Know Before Choosing a Peptide for Dry Eyes

Dry eye disease is one of the most common ocular complaints worldwide, and the standard treatments, cyclosporine drops, lifitegrast, and the newer tear-stimulating agents, help many people without fully resolving the problem for everyone. That gap is part of why peptides have become an increasingly discussed option, from active ophthalmology clinical trials to threads across dry eye communities.

A peptide earned a slot on this list because people use it or are actively discussing using it for dry eyes. That test does not require FDA approval, randomized trial data, or an established telemedicine pathway. FDA-approved compounds, off-label compounded formulations, clinical-stage investigational drugs, and supplements are all eligible. Where a compound's evidence is thin or absent for dry eye specifically, this guide says so plainly. The honest statement of thin evidence is the content, not a reason to leave the compound off the list.

The numbers in front of each entry give the list a spine, but they are not a ranking. The order reflects how prominently each compound appears in research and real-world use for dry eyes, not a recommendation of one over another. Clinical maturity, mechanism, and availability vary substantially across these six compounds, and the right choice for any individual depends on the type of dry eye they have, their health history, and what they work through with a qualified practitioner.

One important note before going further: no peptide eye drops are FDA-approved for treating dry eye disease as of 2026. The clinical candidates here are either still in trials or available only through compounding pharmacies with a physician prescription. Regardless of how a peptide is sourced, injectable vials intended for systemic use are absolutely contraindicated for direct eye application. Only ophthalmic-grade formulations compounded by a licensed pharmacy to ocular sterility standards are appropriate for topical ocular use.

1. Thymosin Beta-4: The Only Peptide With Completed Human Trial Data

Thymosin Beta-4, often called TB-4 and sold in research markets as TB-500, is a 43-amino-acid peptide that occurs naturally in most human cells. In the context of dry eyes, it has been studied under the pharmaceutical name RGN-259 by ReGenTree and RegeneRx, and it stands apart from every other compound on this list because it has completed Phase 2 randomized controlled trials specifically for dry eye disease, with statistically significant results.

Three mechanisms appear to work in parallel. First, Thymosin Beta-4 binds to free actin inside damaged cells and prevents premature polymerization. Think of actin as the internal scaffolding that gives cells their shape: when it stiffens too early, corneal epithelial cells cannot migrate across the surface to close wounds. Thymosin Beta-4 keeps that scaffolding flexible long enough for cells to move where they are needed. Second, it upregulates aquaporin-5 water channels in the lacrimal gland, the structure responsible for producing the watery component of tears, directly stimulating tear secretion. Third, it blocks a subunit of the NF-kB inflammatory signaling pathway, reducing the cycle of chronic surface inflammation that keeps dry eye going long after its original trigger.

The human trial data behind this mechanism is specific and meaningful. In a Phase 2 randomized vehicle-controlled trial in patients with severe aqueous-deficient dry eye associated with chronic graft-versus-host disease, RGN-259 produced a 35 percent reduction in ocular discomfort at day 56 and a 59 percent reduction in corneal fluorescein staining, a measure of surface damage, both statistically significant. Benefits also persisted at 28 days after treatment ended, which the researchers described as relatively fast and long-lasting. No serious adverse events were attributed to the compound. Phase 3 trials have been announced for dry eye disease and neurotrophic keratitis, though published results are not yet available.

In dry eye communities, experience is mixed in the way early-stage treatments often are. Some users combining Thymosin Beta-4 with BPC-157 reported a meaningful reduction in how often they needed artificial tears. Others tried it and found no benefit. One unverified account circulating in a peptide group described a serious adverse event, though no clinical confirmation exists. The community experience is neither a strong endorsement nor a clear warning, and the Phase 2 data remains the more reliable signal.

As of 2026, Thymosin Beta-4 is not FDA-approved for any ophthalmic indication and no New Drug Application has been filed. It is available through compounding pharmacies for off-label use with a physician prescription, formulated as an ophthalmic solution. Some telemedicine providers may facilitate access if a licensed physician determines off-label use is medically appropriate. That physician-directed compounding route is the right pathway for anyone exploring it.

2. LacriPep: Restoring a Natural Tear Protein That Dry Eye Depletes

LacriPep is a synthetic fragment of lacritin, a glycoprotein that occurs naturally in healthy human tears and was first identified at the University of Virginia. Its relevance to dry eyes starts from a specific biological fact: lacritin is measurably deficient in people with dry eye disease, particularly those with Sjögren's syndrome, the autoimmune condition that attacks moisture-producing glands and causes some of the most severe cases of aqueous-deficient dry eye. LacriPep is not masking symptoms from the outside. It is restoring something that should be present and is not.

Lacritin's mechanism operates through a receptor called syndecan-1 on the surface of corneal and conjunctival cells. Under normal conditions, a sugar-chain blockade prevents lacritin from binding. In cells that are damaged or under stress, an enzyme called heparanase clears that blockage and opens the binding site, so the peptide activates selectively in tissues that are signaling distress. Once bound, it triggers a transcription cascade that drives autophagy, the process by which cells clear damaged internal components, and then promotes mitochondrial fusion, which restores the cell's energy-producing capacity. The downstream result is increased basal tear secretion from cells that are functioning normally again rather than compensating around dysfunction.

The clinical evidence for LacriPep is the second strongest in this space. In a Phase 2 first-in-human trial enrolling 204 patients across 35 centers, LacriPep produced a statistically significant reduction in inferior corneal staining and a meaningful drop in burning and stinging scores within two weeks, in patients with primary Sjögren's syndrome dry eye. No serious adverse events were reported. The developer has described this as the largest ophthalmic peptide trial ever conducted in Sjögren's syndrome dry eye.

LacriPep is not commercially available as of 2026. It remains a clinical-stage compound, and access currently runs through clinical trial enrollment or through specialized practitioners who may have compounded formulations available on a case-by-case basis.

3. GHK-Cu: For Meibomian Gland-Driven Evaporative Dry Eye

GHK-Cu is a tripeptide-copper complex found naturally in human plasma that has been studied for decades in wound healing, skin biology, and tissue repair. In the dry eye context, it has emerged as a research candidate specifically for meibomian gland dysfunction, which drives evaporative dry eye and accounts for the large majority of all dry eye cases seen clinically.

The meibomian glands line the upper and lower eyelids and secrete the lipid layer of the tear film, which slows evaporation and stabilizes tear distribution across the eye. When these glands are damaged by chronic oxidative stress, their functional tissue is gradually replaced by fibrosis: stiff, non-functioning material that no longer produces the lipid the tear film needs. GHK-Cu addresses this from two directions. It scavenges reactive oxygen species, acting as a direct antioxidant that protects the lipid-producing meibocytes from ongoing oxidative damage. At the same time, it promotes controlled collagen remodeling, which can gradually reverse the fibrotic buildup and restore normal gland architecture. The combination of protecting against new damage while remodeling existing damage is what makes it mechanistically compelling for this particular type of dry eye.

The limitation is that all of this evidence comes from preclinical work. No human clinical trials specifically targeting meibomian gland dysfunction or dry eye disease have been published for GHK-Cu as of 2026. Researchers working in this area describe it as a leading preclinical candidate for the MGD indication, but that candidate status has not yet produced a published human trial. GHK-Cu has a broad following in the peptide community for skin and wound-healing applications, and some users have extended it to ocular surface protocols. The evidence base for dry eyes specifically is animal models and mechanistic reasoning, and that is the honest status as of now.

4. BPC-157: Corneal Wound Healing and Neurotrophic Support

BPC-157, which stands for Body Protection Compound-157, is a synthetic pentadecapeptide of fifteen amino acids derived from a sequence found in gastric juice. It has one of the broadest tissue-healing evidence bases of any peptide in community and research use, with animal data spanning tendon, gut, muscle, and corneal wound healing.

For dry eyes, the mechanism of interest centers on VEGF upregulation. VEGF, vascular endothelial growth factor, is the body's primary signal for building new blood vessels, and BPC-157 appears to upregulate both VEGF and its main receptor. In animal studies of corneal damage, this translated into new vessel growth at the limbal border, the ring of tissue where the cornea meets the white of the eye, improving nutrient delivery to damaged tissue and supporting closure of persistent epithelial defects. BPC-157 also carries anti-inflammatory properties that reduce the surface inflammation involved in the self-perpetuating dry eye cycle.

The evidence limitation here deserves direct statement: no human clinical trials for BPC-157 in ophthalmic applications have been published as of 2026. The corneal evidence is animal studies, and the translation to human physiology has not been established through controlled research. Community protocols have paired it with Thymosin Beta-4, and at least one community account reported a reduction in daily artificial tear use from that combination, though this is a single observational report rather than a trial outcome.

BPC-157 is classified as a research compound. It is available through compounding pharmacies for off-label ophthalmic use with a physician prescription, and through research-chemical channels where the regulatory picture for human self-administration is genuinely complex. The physician-directed compounding route is the appropriate pathway. BPC-157 appears on this list because it is consistently discussed in dry eye communities and its corneal wound-healing mechanism is plausible and grounded in animal research, particularly for cases where surface damage or neurotrophic keratopathy is part of the picture alongside baseline dryness.

5. ST-100: A Collagen-Repair Approach With Mixed Phase 3 Results

ST-100, also called vezocolmitide, is a collagen mimetic peptide developed by Sterling Therapeutics. Its mechanism differs from every other compound on this list: rather than stimulating tear production, scavenging oxidative damage, or reducing inflammation directly, it works by physically intercalating into damaged corneal collagen and helping restore the correct triple-helix structure that gives the tissue its integrity.

The reason corneal collagen repair matters for dry eye is indirect but important. The corneal surface contains a dense network of nerve endings that drive the parasympathetic reflex responsible for stimulating the lacrimal gland to produce tears. That nerve network depends on an intact extracellular matrix, the structural scaffold beneath the surface epithelium. When chronic inflammation, prior surgery, or injury degrades that matrix, the nerve bed becomes compromised, the reflex weakens, and tear production falls. ST-100 targets the structural foundation so that normal neural signaling can resume rather than treating the downstream deficit.

In Phase 3 clinical trials with 175 adults, ST-100 produced clinically meaningful symptom relief beginning around day four, with significant improvements in corneal fluorescein staining at week one. The Schirmer responder rate, measuring meaningful gains in tear production versus baseline, was substantially better than placebo in secondary analyses. However, the primary endpoint was not met statistically, largely because of an unexpectedly strong response in the vehicle-controlled group. The Phase 3 results are therefore mixed: clear secondary signals, primary endpoint failure.

ST-100 is not commercially available and is not FDA-approved. Its pipeline status after the Phase 3 outcome is not clearly established as of 2026. It is included here because it reached Phase 3 and produced observable clinical benefit in real patients, which places it firmly within the active peptide-for-dry-eyes conversation among researchers and clinicians tracking the space.

6. Visoluten: An Ocular Bioregulator Used in Eye Health Stacks

Visoluten is a peptide bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology as part of the Russian peptide bioregulator research tradition associated with Professor Vladimir Khavinson and colleagues. Peptide bioregulators are short peptides, typically two to four amino acids in length, derived from organ-specific animal tissue extracts. The theory behind them is that they provide tissue-specific regulatory signals to corresponding tissues when taken orally. Visoluten is the retinal bioregulator, formulated from bovine retinal tissue extract.

The proposed mechanism involves epigenetic-style regulation of gene expression in target tissues, with the retina and broader visual system as the primary site of action. Users who incorporate Visoluten into ocular health protocols generally describe it as a general visual system support compound, often stacked with other peptides or supplements rather than used as a standalone treatment for any specific condition.

The honest evidence picture here requires plain language. No clinical trial data specifically addressing dry eye disease has been published for Visoluten as of 2026. Its research base targets retinal tissue, not the lacrimal gland or the corneal surface, which are the primary dysfunctional sites in dry eye disease. The mechanisms proposed for its effects on retinal cells do not directly address the tear film deficiency or ocular surface inflammation that drives dry eye symptoms. This is a meaningful gap for anyone who came to this article looking for dry eye relief.

Visoluten is used and discussed in peptide communities focused on ocular health, visual aging, and eye longevity, including in contexts where dry eyes are mentioned alongside broader visual concerns. It is available as an oral supplement in some markets and through specialty suppliers, and it is not regulated as a drug in the United States. It is on this list because it is actively discussed in the peptides-and-eye-health conversation and the inclusion criterion for this guide is use and discussion, not clinical validation. Readers considering it specifically for dry eye symptoms should know that better-evidenced options exist for that application, and that Visoluten's proposed benefits target a different part of the visual system than the one dry eye disease primarily affects.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides available as eye drops right now?

As of 2026, no peptide eye drops are FDA-approved for treating dry eye disease, so none are available over the counter or through a standard pharmacy as a dry eye treatment. Thymosin Beta-4 and BPC-157 can be accessed through compounding pharmacies as off-label ophthalmic formulations with a physician prescription. Clinical-stage compounds like LacriPep and ST-100 are accessible only through clinical trial enrollment or, in rare cases, through specialized practitioners. Visoluten is sold as an oral supplement in some markets outside the US.

Is it safe to use peptides directly in your eyes?

Safety depends entirely on the formulation. Ophthalmic-grade compounded solutions prepared by a licensed pharmacy to ocular sterility standards have shown a generally clean profile in trials, with mild transient stinging being the most commonly reported effect. Injectable peptide vials, whether sold as research chemicals or used systemically, must never be placed in the eyes; they are not formulated or sterilized for ocular use and carry real risk of serious irritation, contamination, or corneal damage. The only appropriate route for any peptide ocular application is a formulation specifically compounded for ophthalmic use under physician oversight.

How do these peptides differ from standard prescription dry eye drops?

Most FDA-approved dry eye treatments work as anti-inflammatories that reduce immune-mediated surface damage, like cyclosporine and lifitegrast, or as agents that stimulate the trigeminal nerve to prompt tear production, like varenicline nasal spray. The peptides on this list generally target more upstream biology: repairing corneal surface tissue directly, restoring a deficient natural tear protein, protecting oil-producing glands from oxidative damage, or rebuilding the structural matrix that supports normal tear-stimulating nerve signals. Whether that upstream approach produces better outcomes than standard care depends on the subtype of dry eye and the individual's specific deficiencies, which is part of why these compounds are still in development rather than standard practice.

Why are some of these still in animal research if dry eye is so common?

The path from animal evidence to an approved ophthalmic treatment is long and expensive. Ophthalmic formulations require specialized delivery chemistry, strict sterility standards, and clinical endpoints distinct from those used for systemic medications, all of which raise the cost and complexity of clinical development. GHK-Cu and BPC-157 have compelling preclinical evidence but have not yet secured the pharmaceutical investment needed for sponsored human trials. Being at the preclinical stage does not necessarily mean the mechanism is wrong; it often means the development pathway has not been fully resourced. The number of active sponsored trials in this space as of 2026 suggests that investment is growing.

Can peptides be used alongside existing dry eye treatments?

Some community users report combining Thymosin Beta-4 and BPC-157 with their existing treatment regimens and noticing a reduction in how frequently they need artificial tears, though this is anecdotal experience rather than controlled trial data. Whether any peptide can or should be combined with a prescription dry eye treatment is a conversation for a qualified practitioner who knows your complete medical picture. The mechanisms of the compounds on this list are generally different enough from standard anti-inflammatory and nerve-stimulating approaches that the pharmacological interaction is not straightforward to predict, which is all the more reason that combination use belongs in a clinical conversation rather than a self-directed protocol.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for dry eyes in one place.